Vertex kidney drug povetacicept succeeds in trial for IgAN
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters…
Eli Lilly launches program to boost employer coverage of obesity drugs
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the…
Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly
Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its…
These 4 charts show the scale of Novo Nordisk’s woes
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most…
What’s next for Novo Nordisk’s obesity drug CagriSema
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
Eli Lilly launches Zepbound obesity drug pen with one month of doses
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March…
Gilead to acquire cancer therapy developer Arcellx
A Gilead Sciences office is shown in Foster City, California, U.S. May 1, 2018. Stephen Lam | Reuters…
Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion
Hims & Hers Health said on Thursday it will acquire Australian digital health company Eucalyptus in a deal…
More drugs should be over-the-counter
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter”…
Novo Nordisk sues Hims & Hers over compounded obesity drugs
Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper,…
CVS Health (CVS) earnings Q4 2025
A pedestrian walks by a CVS store in Greenbrae, California, on July 31, 2025. Justin Sullivan | Getty…
Pfizer execs talk Metsera obesity drug
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in…